HUTCHMED (China) Ltd
HMDCF$2.49B
Mid CapNASDAQBiotechnology🇺🇸North America1.8K employees
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Dec 25, 2026
34wMarket Overview
Stock performance and key metrics
HMDCF News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
HMPL-760
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
surufatinib
Tumors
HMPL-A580
Solid Tumors, Adult
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
HMPL-760 | Phase 3 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | - | - |
surufatinib | Phase 2 | Tumors | - | - |
HMPL-A580 | Phase 2 | Solid Tumors, Adult | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply